Literature DB >> 31327827

Aseptic Meningitis as an Initial Manifestation of Anti-myelin Oligodendrocyte Glycoprotein Antibody-associated Disease.

Takehiro Suzuki1, Kota Maekawa1,2, Ko Matsuo1, Masayoshi Yamasaki1, Masunari Shibata2, Toshiyuki Takahashi3,4, Yutaka Naito1.   

Abstract

Antibody against myelin oligodendrocyte glycoprotein (MOG-IgG) associated encephalitis is an important syndrome associated with MOG-IgG. However, there have been no reports of MOG-IgG-associated optic neuritis or demyelination following meningitis without encephalitic symptoms. A 55-year-old woman presented to our hospital with headache, nausea, fever, and nuchal rigidity that had persisted for more than a month. She was hospitalized due to aseptic meningitis and recovered with conservative therapy. However, she was re-admitted due to left optic neuritis and demyelinating lesions. We diagnosed MOG-IgG-associated neuromyelitis optica spectrum disorder (NMOSD). She responded to treatment with intravenous methylprednisolone and oral prednisolone. Aseptic meningitis may be an initial manifestation of MOG-IgG-positive NMOSD.

Entities:  

Keywords:  anti-myelin oligodendrocyte glycoprotein antibody; aseptic meningitis; neuromyelitis optica spectrum disorder; optic neuritis

Mesh:

Substances:

Year:  2019        PMID: 31327827      PMCID: PMC6911747          DOI: 10.2169/internalmedicine.2845-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Myelin-oligodendrocyte glycoprotein (MOG) is exclusively expressed on the surface of oligodendrocytes in the central nervous system (CNS). Anti-MOG antibody (MOG-IgG) is predominantly detected in pediatric acute disseminated encephalomyelitis, recurrent optic neuritis, and aquaporin-4-antibody-seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG-associated encephalitis is an important clinical syndrome associated with MOG-IgG and may be a bridging element in the emerging spectrum of MOG-IgG-associated syndrome (1). However, there have been no reports of MOG-IgG-associated meningitis without encephalitic symptoms followed by optic neuritis or demyelination. We herein report a case of MOG-IgG associated NMOSD in a patient with prolonged meningeal symptoms without any encephalitic manifestations for 2 months before the development of optic neuritis and demyelinating lesions.

Case Report

A 55-year-old woman visited our hospital complaining of headache, nausea, vomiting, and fever, which had persisted for more than one month; with no recent history of illness or drug use and was alert. The patient had no focal neurological deficits, with the exception of nuchal rigidity. A peripheral blood smear revealed leukocytosis (white blood cell count; 9,900 /μL). The cerebrospinal fluid (CSF) pressure was 25 cm of H2O, the cell count was 190/mm3 (monocytes, 127/mm3), and the protein level was 78 mg/dL. Magnetic resonance imaging (MRI) revealed hyperintensity without edema in the superficial cortex on fluid-attenuated inversion recovery (FLAIR) images (Figure a). No bacteria or fungi were detected in the patient's blood or CSF. Additionally, the interferon-gamma release assay for tuberculosis was negative. The patient's herpes simplex virus and varicella zoster virus antibody levels were not elevated and the patient was negative for anti-neutrophil cytoplasmic antibodies. The patient was diagnosed with aseptic meningitis and hospitalized for treatment. The patient received conservative therapy and by day 6 of hospitalization, her CSF cell count was 60/mm3 (monocyte; 51/mm3) and her protein level was 50 mg/dL. The patient recovered and was discharged on the 13th day after admission.
Figure.

Head MRI at first and second admission. Hyperintensity was detected in the superficial cortex on FLAIR at the first admission (a). Brain contrast MRI with gadolinium enhancement showed left optic nerve and right optic tract swelling in FLAIR and T1-weighted images on second admission (b). Demyelination lesions were observed in the left prefrontal and right prefrontal-parietal subcortex (c). MRI: magnetic resonance imaging, FLAIR: fluid-attenuated inversion recovery

Head MRI at first and second admission. Hyperintensity was detected in the superficial cortex on FLAIR at the first admission (a). Brain contrast MRI with gadolinium enhancement showed left optic nerve and right optic tract swelling in FLAIR and T1-weighted images on second admission (b). Demyelination lesions were observed in the left prefrontal and right prefrontal-parietal subcortex (c). MRI: magnetic resonance imaging, FLAIR: fluid-attenuated inversion recovery At seven days after her initial discharge, the patient was re-admitted to our hospital due to severe left-eye visual impairment and loss of direct light reflex. The patient's CSF cell count was 26/mm3 (monocyte; 25/mm3) and her protein level was 35 mg/dL, which was better than previously recorded. MRI with gadolinium enhancement revealed left optic nerve and right optic tract swelling on FLAIR and T1-weighted imaging (Figure b). Moreover, hyperintensity was observed in the left prefrontal and right prefronto-parietal subcortex (Figure c). The patient was negative for autoantibodies, including anti-aquaporin-4 antibodies; however, an in-house live cell-based assay was positive for MOG-IgG. The patient's myelin basic protein (MBP) level was normal and oligoclonal IgG bands were evident. We diagnosed the patient with MOG-IgG associated NMOSD and initiated treatment with methylprednisolone (1,000 mg/day for 3 days) followed by oral prednisolone (45 mg/kg). The patient's symptoms and MRI gradually improved without any side effects. After continuing oral prednisolone (30 mg/day), the patient was discharged on the 39th day after the 2nd admission.

Discussion

In the present case, prolonged meningeal symptoms occurred for 2 months. No neurological deficit was observed and the meningeal sign was evident. MOG-IgG was not measured at this time. The patient's symptoms gradually improved with conservative therapy; however, MOG-IgG-positive optic neuritis and demyelinating lesions were diagnosed later. Akaishi et al. reported that optic neuritis, encephalitis, and myelitis were more frequently present in MOG-IgG-associated diseases (2). This case was a rare type of MOG-IgG-associated disorder in adults presenting as meningitis and optic neuritis. While the association of MOG-IgG with optic neuritis and myelitis is now well established, very less is known about the extra-opticospinal manifestations of MOG-IgG-related autoimmunity (3, 4). Previous studies have reported rare cases of MOG-IgG-associated encephalitis (1, 5, 6). However, in the present case, encephalitic symptoms such as seizures, consciousness disturbance, and focal signs were not seen, and thus the patient was diagnosed with meningitis. To the best of our knowledge, there have been no reports of optic neuritis or demyelination after meningitis. Narayan et al. reported two cases, wherein MOG-IgG-related syndrome presented with symptoms of meningitis and optic neuritis (7). However, their symptoms occurred at the same time, whereas meningitis preceded optic neuritis by more than one month in our patient. We therefore report the first case in which no symptoms other than aseptic meningitis were evident prior to MOG-IgG positive NMOSD. Ogawa et al. suggested that there is a possibility in which MOG-IgG itself may not be directly associated with cerebral cortical encephalitis with epileptic seizures and that another autoimmune disorder involving an unknown autoantibody may coexist with MOG-IgG positivity and might be responsible for encephalitis (5). Thus, in our patient, MOG-IgG and other autoantibodies may have been associated with the aseptic meningitis preceding optic neuritis and demyelination (other autoantibodies were not measured). We conclude that our case and various other previous cases showed MOG-IgG-associated encephalomeningitis and that the primary difference between these cases was the degree of inflammation. In this case, the FLAIR signal increased with enhancement of the subcortex, which means that she had encephalitis at that time. Because of the lower degree of severity, the symptoms of encephalitis were not evident. A preceding infectious prodrome has been reported in 47% of MOG-IgG positive cases (6). The role of infectious agents in triggering MOG-IgG production is still unclear. It is possible that the patient's aseptic meningitis was infectious meningitis preceding optic neuritis and demyelination; however, bacterial, fungal, herpes-viral, and drug-induced meningitis were excluded at that time. We did not investigate the possibility of enterovirus infection. Although enterovirus meningitis usually improves within 7-10 days, in our patient meningeal symptoms persisted for approximately two months and the clinical course was atypical for viral meningitis (8). Prior infection with other types of viral meningitis unrelated to MOG-IgG could not be denied in this case because MOG-IgG was not measured previously; neither electroencephalography nor single positron emission computed tomography was advised at the first onset of meningitis. On the other hand, the long duration of the symptoms of meningitis and the hyperintensity of the superficial cortex on FLAIR may be pathophysiologically similar to the findings in the previous study of MOG-IgG-associated cerebral cortical encephalopathy (5). Although the normal CSF-MBP level indicates that the demyelination was mild, the evident oligoclonal IgG band showed chronic inflammation of the CNS, which is indicative of possible continuous meningitis. Thus, it is possible that the aseptic meningitis in our patient was associated with autoantibodies and not infection.

Conclusion

Aseptic meningitis may be an initial manifestation of MOG-IgG-positive NMOSD. MOG-IgG may be partially associated with benign aseptic meningitis that persists for longer than usual. In order to validate these results, further studies should be performed to investigate the results of autoantibody screening tests in patients with aseptic meningitis and to assess the effectiveness of MOG-IgG measurement as a prognostic factor.

The authors state that they have no Conflict of Interest (COI).
  8 in total

1.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Authors:  Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

2.  Enteroviral meningitis: natural history and outcome of pleconaril therapy.

Authors:  R A Desmond; N A Accortt; L Talley; S A Villano; S-J Soong; R J Whitley
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations.

Authors:  Ram N Narayan; Cynthia Wang; Peter Sguigna; Khalil Husari; Benjamin Greenberg
Journal:  Mult Scler Relat Disord       Date:  2018-10-03       Impact factor: 4.339

Review 4.  Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein.

Authors:  Tetsuya Akaishi; Douglas Kazutoshi Sato; Toshiyuki Takahashi; Ichiro Nakashima
Journal:  Neurochem Int       Date:  2018-10-23       Impact factor: 3.921

5.  Persistence of immunopathological and radiological traits in multiple sclerosis.

Authors:  Fatima B König; Brigitte Wildemann; Stefan Nessler; Dun Zhou; Bernhard Hemmer; Imke Metz; Hans-Peter Hartung; Bernd C Kieseier; Wolfgang Brück
Journal:  Arch Neurol       Date:  2008-11

6.  Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.

Authors:  Russell C Dale; Esther M Tantsis; Vera Merheb; Raani-Yogeeta A Kumaran; Nese Sinmaz; Karrnan Pathmanandavel; Sudarshini Ramanathan; David R Booth; Louise A Wienholt; Kristina Prelog; Damien R Clark; Gilles J Guillemin; Chai K Lim; Emily K Mathey; Fabienne Brilot
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-05-22

7.  MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.

Authors:  Ryo Ogawa; Ichiro Nakashima; Toshiyuki Takahashi; Kimihiko Kaneko; Tetsuya Akaishi; Yoshiki Takai; Douglas Kazutoshi Sato; Shuhei Nishiyama; Tatsuro Misu; Hiroshi Kuroda; Masashi Aoki; Kazuo Fujihara
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-01-16

Review 8.  MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.

Authors:  Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato
Journal:  Front Neurol       Date:  2018-04-04       Impact factor: 4.003

  8 in total
  5 in total

1.  Aseptic Meningitis Followed by Bilateral Optic Neuritis: An Uncommon Phenotype of MOGAD.

Authors:  Rashmi Devaraj; Peerzada Shafi; Chinmay Nagesh; Suvarna Alladi; Parthasarathy Satishchandra
Journal:  Neurol Clin Pract       Date:  2021-10

2.  Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report.

Authors:  Chenyang Zhang; Kang Zhang; Bing Chen; Jiao Yin; Miaomiao Dong; Yixin Qin; Xiao Yang
Journal:  BMC Neurol       Date:  2021-03-09       Impact factor: 2.474

Review 3.  Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD).

Authors:  Yunjie Li; Xia Liu; Jingxuan Wang; Chao Pan; Zhouping Tang
Journal:  Front Aging Neurosci       Date:  2022-03-15       Impact factor: 5.750

4.  A tearfully painful darkness.

Authors:  Lakshmi Leishangthem; Shannon Beres; Heather E Moss; John Chen
Journal:  Surv Ophthalmol       Date:  2020-06-12       Impact factor: 6.048

5.  Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis Prior to the Onset of Optic Neuritis.

Authors:  Takuya Ataka; Noriyuki Kimura; Etsuro Matsubara
Journal:  Intern Med       Date:  2021-06-12       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.